| Study ID | Mean (SD)/median (IQR)/range systolic BP, mmHg | Mean (SD)/median (IQR)/range diastolic BP (SD), mmHg | Smoking: current and/or past, % | Medications, % | Comorbidities, % | Mean (SD)/median (IQR)/range FPG, mmol/L | Mean (SD)/median (IQR)/range 2‐h glucose, mmol/L | Mean (SD)/median (IQR)/range HbA1c, % | Notes |
| Admiraal 2014 | — | — | 38 26 41 41 | — | Hypertension: 26 26 32 19 |
5.2 5.3 5.2 5.3 | — | — | Total cohort South‐Asian Surinamese African Surinamese "Ethnic Dutch" |
| Aekplakorn 2006 | — | — | 42 | — | Hypertension: 33 | — | — | — | — |
| Ammari 1998 | — | — | — | — | Hypertension: 47 | — | — | — | — |
| Anjana 2015 | 129 (21) | 78 (11) | 13 | — | — | 5.2 (0.6) | 8.7 (1.4) | 6.2 (0.7) | — |
| Bae 2011 | 113 (14) | 76 (10) | — | — | — | 5.3 (0.5) | — | 5.4 (0.3) | — |
| Baena‐Diez 2011 | — | — | 33 | — | Hypercholesterolaemia: 38 Hypertriglyceridaemia: 15 Hypertension: 55 | — | — | — | — |
| Bai 1999 | — | — | — | — | — | — | — | — | — |
| Bergman 2016 | 128 (16) | 84 (10) | 38 | — | — | 5.2 (0.5) | 8.6 (1.0) | — | — |
| Bonora 2011 | — | — | — | — | — | — | — | — | — |
| Cederberg 2010 | Men: 142 Women: 142 | Men: 80 Women: 79 | Men: 18 Women: 15 | — | — | Men: 5.0 Women: 5.0 | Men: 6.8 Women: 7.0 | — | — |
| Chamnan 2011 | 139 (17) | 84 (11) | 15 | BP lowering: 21 Corticosteroids: 4 | — | — | — | — | — |
| Charles 1997 | — | — | — | — | — | 6.6 (0.8) | 9.3 (0.9) | — | — |
| Chen 2003 | — | — | 38 | — | Hypertension: 46 | — | — | — | — |
| Chen 2017 | — | — | 12–24 | — | Hypertension: 28–55 | 5.1–6.1 | 5.9–9.2 | — | Range for i‐IFG, i‐IGT and IFG/IGT cohorts separated by < 40 years and > 60 years |
| Coronado‐Malagon 2009 | — | — | — | — | — | 5.9 (0.3) | — | — | — |
| Cugati 2007 | 146 | 83 | — | — | — | 5 | — | — | — |
| De Abreu 2015 | 128 (IQR 114–140) | 79 (IQR 72–86) | 13 | — | Hypertension: 43 | 5.3 (IQR 5.0–5.8) | — | — | — |
| Den Biggelaar 2016 | 141 (IQR 132–155) | 83 (IQR 78–92) | 18 | — | — | 6.0 (IQR 5.5–6.3) | 8.8 (IQR 7.8–9.9) | 5.8 (IQR 5.6–6.1) | — |
| Derakhshan 2016 | — | — | 26 | — | — | — | — | — | — |
| Dowse 1991 | — | — | — | — | — | — | — | — | — |
| Ferrannini 2009 | 118–128 | 71–78 | — | — | — | 4.9–6.4 | 6.7–9.5 | — | Range for i‐IFG5.6, i‐IFG6.1, i‐IGT, IGT5.6 and IGT6.1 cohorts |
| Filippatos 2016 | 127 (17) | 82 (10) | 62 | — | Hypertension: 36 Hypercholesterolaemia: 54 |
5.9 (0.3) | — | — | — |
| Forouhi 2007 | 136 (16) | 82 (10) | 52 | — | — | — | — | — | — |
| Garcia 2016 | — | — | 58 | — | — | — | — | — | — |
| Gautier 2010 | — | — | — | — | — | — | — | — | — |
| Gomez‐Arbelaez 2015 | — | — | — | — | — | 5.2 (0.7) | 6.0 (1.8) | 6.5 (1.3) | — |
| Guerrero‐Romero 2006 | — | — | — | — | Dyslipidaemia: 41 Hypertension: 24 | 6.4 (0.6) | — | — | — |
| Han 2017 | 120 (17) 119 (18) 124 (18) |
78 (12) 76 (12) 80 (11) |
64 34 59 |
— | Hypertension: 28 27 36 |
5.9 (0.3) 4.8 (0.4) 5.9 (0.3) |
6.1 (1.2) 8.9 (0.9) 9.3 (0.9) |
5.5 (0.4) 5.5 (0.4) 5.7 (0.4) |
i‐IFG5.6 i‐IGT IFG/IGT |
| Hanley 2005 | 132 (20) | 79 (10) | — | BP lowering: 38 Lipid lowering: 7 | — | 5.9 (0.7) | 8.5 (1.7) | — | — |
| Heianza 2012 | 125 (16) | 76 (11) | — | — | — | 5.3 (0.5) | 5.3 (0.3) | — | |
| Inoue 1996 | 142 (9) | 73 (7) | — | — | — | — | — | — | — |
| Janghorbani 2015 | 116–117 | 76–77 | — | — | Hypertension: 20–23 | 5.1–61 | 5.9–9.2 | 5.1–5.3 | Range for i‐IFG, i‐IGT and IFG/IGT cohorts |
| Jaruratanasirikul 2016 | 124 (15) | 77 (9) | — | — | — | — | — | — | — |
| Jeong 2010 | 139 (21) | 87 (12) | 43 | — | — | — | — | 5.7 (0.5) | — |
| Jiamjarasrangsi 2008a | — | — | 4 | — | — | — | — | — | — |
| Kim 2005 | — | — | — | — | — | 6.4 (0.2) | — | — | — |
| Kim 2008 | 128/132 | 80/83 | — | — | — | 5.8/6.4 | — | — | — |
| Kim 2014 | 127–129 | 78 | 20–31 | — | — | — | — | — | Range for i‐IFG, i‐IGT, IFG/IGT and i‐HbA1c cohorts |
| Kim 2016a | 116–120 | 72–75 | 24–25 | — | — | 5.1–5.9 | — | 5.3–5.8 | Range for IFG and HbA1c cohorts |
| Kleber 2010 | 120 (16) | 73 (13) | — | — | — | 5.1 (1.1) | 8.5 | 5.6 (0.7) | — |
| Kleber 2011 | 120 (14) | 73 (12) | — | — | — | 4.8 (0.4) | 8.4 (0.6) | — | — |
| Ko 1999 | — | — | — | — | — | — | — | — | — |
| Ko 2001 | 125 (21) | 78 (10) | 2 | — | — | 6.5 (0.3) | 9.1 (2.1) | 6.2 (0.6) | — |
| Larsson 2000 | — | — | — | — | — | 4.7/5.5/5.5 | 8.6/6.8/8.7 | — | — |
| Latifi 2016 | — | — | — | — | Hypertension: 40 | — | — | — | — |
| Lecomte 2007 | 135 (13) | 81 (10) | 23 | — | Hypertension: 48 | 6.4 (0.2) | — | — | — |
| Lee 2016 | 125 (15) | 81 (11) | 20 | — | Hypertension: 22 | — | — | 5.9 (0.2) | — |
| Leiva 2014 | 134 (16) | 77 (10) | — | — | — | — | — | — | — |
| Levitzky 2008 | Women: 122 Men: 127 | — | Women: 29 Men: 28 | Antihypertensives: Women: 14 Men: 16 | Hypertension: Women: 26 Men: 35 |
— | — | — | — |
| Li 2003 | 136–138 | 85–87 | — | — | — | 5.4–6.4 | 6.8–9.1 | — | Range for i‐IFG, i‐IGT and IFG/IGT cohorts |
| Ligthart 2016 | 145 (21) | 81 (12) | 50 | BP lowering: 33 Lipid lowering: 18 | Stroke: 3
CHD: 8 Hypertension: 64 |
— | — | — | — |
| Lipska 2013 | 140–143 | — | 54–65 | — | — | 5.1–6.1 | — | 5.3–5.9 | Range for i‐IFG, i‐HbA1c and IFG/HbA1c cohorts |
| Liu 2008 | Men: 126 Women: 124 | Men: 80 Women: 77 | — | — | — | Men: 5.3 Women: 5.4 | — | — | — |
| Liu 2014 | 132 (16) | 82 (8) | — | — | — | 5.8 (0.8) | 9.2 (1.2) | — | — |
| Liu 2016 | — | — | — | — | — | — | — | — | — |
| Liu 2017 | 128 (21) | 81 (11) | 37 | — | — | 5.9 (0.4) | — | — | — |
| Lorenzo 2003 | 124 | 75 | — | — | — | 5.3 | 7.6 | — | — |
| Lyssenko 2005 | 140 | 85 (11) | — | — | — | 6.3 (IQR 5.8–6.6) | 8.3 (1.6) | 5.7 (0.4) | — |
| Magliano 2008 | — | — | 48 | — | — | 6 | 8 | 5.5 | — |
| Man 2017 | 145 (20) | 80 (12) | 13 | — | Hypertension: 74 | — | — | — | — |
| Marshall 1994 | — | — | — | — | — | 6.1 | 9.5 | — | — |
| McNeely 2003 | 139 137 | 80 80 | — | — | — | 5.5 5.6 | 9.0 8.8 | — | 5–6 years follow‐up 10 years follow‐up |
| Meigs 2003 | — | — | — | — | — | — | — | — | — |
| Mohan 2008 | 127 (19) | 81 (11) | — | — | — | 4.5 (0.6) | — | — | — |
| Motala 2003 | 119 (19) | 78 (13) | — | — | — | 4.6 (1.8) | 6.2 (3.8) | — | — |
| Motta 2010 | — | — | — | — | — | — | — | — | — |
| Mykkänen 1993 | 159 | 84 | 1 | Antihypertensives: 24 | Hypertension: 47 | 6.2 | 8.4 | — | — |
| Nakagami 2016 | 134 (18) | 82 (12) | 35 | — | — | 6.0 (0.6) | — | 6.0 (0.3) | — |
| Nakanishi 2004 | 133 (16) | 81 (11) | 53 | — | Dyslipidaemia: 40 Proteinuria: 5 Hypertension: 35 | 6.4 (0.2) | — | — | — |
| Noda 2010 | — | — | — | — | — | Men: 5.4 Women: 5.2 | — | Men: 5.0 Women: 5.1 | — |
| Park 2006 | — | — | — | — | — | 6.0 (0.3) | — | — | — |
| Peterson 2017 | — | 75 (11) | — | — | — | — | — | 5.5 (0.4) | — |
| Qian 2012 | 126 (21) | 81 (12) | — | — | — | 5.2 (0.7) | 6.1 (1.5) | — | — |
| Rajala 2000 | — | — | — | — | Hypertension: 49 | — | — | — | — |
| Ramachandran 1986 | — | — | — | — | — | — | — | — | — |
| Rasmussen 2008 | 140–142 | — | — | — | — | — | — | — | Range for IFG and IGT cohorts |
| Rathmann 2009 | 133 (19) | 80 (10) | 49 | Lipid lowering: 11 | Hypertension: 49 | 5.5 (0.5) | 6.3 (1.7) | 5.6 (0.4) | — |
| Rijkelijkhuizen 2007 | 139–145 | 84–85 | — | — | — | — | — | — | Range for IFG5.6 and IFG6.1 cohorts |
| Sadeghi 2015 | 127 (21) | 81 (11) | 14 | — | — | 5.7 (0.7) | 8.4 (1.5) | — | — |
| Sasaki 1982 | — | — | — | — | — | 5.6 (0.9) | 9.0 (0.9) | — | — |
| Sato 2009 | — | — | 91 | — | — | 6.0 (0.6) | — | 5.6 (0.6) | — |
| Schranz 1989 | — | — | — | — | — | Women: 7.2 Men: 6.2 | Women: 10.8 Men: 9.7 | — | — |
| Sharifi 2013 | 130 (12) | 79 (8) | 5 | — | Hypertriglyceridaemia: 48 Hypertension: 25 | — | — | — | — |
| Shin 1997 | 130 | 84 | — | — | — | 6.1 | 6.7 | — | — |
| Söderberg 2004 | 125 | 77 | 27 | — | — | 5.5 | 6.5 | — | — |
| Song 2015 | 123–127 | 76–80 | 2–27 | — | Dyslipidaemia: 64–66 Hypertension: 35–44 | — | — | 5.7–5.8 | Ranges for male and female cohorts |
| Song 2016a | 134 (20) | 85 (12) | 23 | — | — | 6.0 (0.4) | 5.9 (1.6) | — | — |
| Soriguer 2008 | — | — | — | — | — | — | — | — | — |
| Stengard 1992 | 156 | 88 | — | — | Hypertension: 53 | 5.4 (1.1) | 9.7 (0.8) | — | — |
| Toshihiro 2008 | 126 (12) | 81 (10) | 47 | — | — | 6.1 (0.6) | 8.8 (1.3) | — | — |
| Vaccaro 1999 | — | — | — | — | — | 4.2 (0.8) | 4.5 (1.7) | — | — |
| Valdes 2008 | 135–144 | 84–92 | — | — | — | 5.8–6.4 | 6.4–7.3 | 4.9–5.1 | Ranges for IFG5.6 and IFG6.1 cohorts |
| Vijayakumar 2017 | — | — | — | — | — | A: 5.4/C: 5.2 | A: 6.7/C: 6.5 | A: 5.8/C: 5.7 | — |
| Viswanathan 2007 | — | — | — | — | — | 6.1 (0.7) | 8.9 (1.0) | — | — |
| Wang 2007 | 124 (19) | 78 (11) | 28 | — | Hypertension: 36 | 5.8 (0.9) | 7.4 (1.7) | — | — |
| Wang 2011 | — | — | — | — | — | — | — | — | — |
| Warren 2017 | — | — | 22 | — | Hypertension: 38 | 6.0 (0.4) | — | 5.6 (0.4) | Data for cohort 1 (IFG5.6) |
| Wat 2001 | 126 | 78 | — | — | — | 5.4 | 8.9 | — | — |
| Weiss 2005 | — | — | — | — | — | 5.2 | 8.9 | — | — |
| Wheelock 2016 | — | — | — | — | — | — | 5.4 (1.2) | — | — |
| Wong 2003 | 125 | 74 | 24 | — | — | 5.7 | 8.9 | — | — |
| Yeboah 2011 | 132 (21) | 74 (11) | 50 | BP lowering: 56 Lipid lowering (statins): 17 | — | 6.0 (0.4) | — | — | — |
| Zethelius 2004 | — | — | — | — | — | 5.7 (0.7) | 7.9 (1.9) | — | — |
| 2‐h: 2‐h measurement after an OGTT; BP: blood pressure; CHD: coronary heart disease; FG: fasting glucose; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0: HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i‐: isolated; IFG5.6/6.1: impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L);IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IQR: interquartile range; OGTT: oral glucose tolerance test; SD: standard deviation | |||||||||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.